Cargando…
A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication
The aim of this study was to evaluate whether patients with type 2 diabetes (T2D) who had stopped attending their diabetes treatment system (referred to as “lost to follow-up”, LTF) but who succeeded in improving their glycaemic control after returning to the diabetes treatment system had changes in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448891/ https://www.ncbi.nlm.nih.gov/pubmed/32498629 http://dx.doi.org/10.1080/22423982.2020.1773127 |
_version_ | 1783574562382807040 |
---|---|
author | Kauppila, Timo Laine, Merja K. Honkasalo, Mikko Raina, Marko Eriksson, Johan G. |
author_facet | Kauppila, Timo Laine, Merja K. Honkasalo, Mikko Raina, Marko Eriksson, Johan G. |
author_sort | Kauppila, Timo |
collection | PubMed |
description | The aim of this study was to evaluate whether patients with type 2 diabetes (T2D) who had stopped attending their diabetes treatment system (referred to as “lost to follow-up”, LTF) but who succeeded in improving their glycaemic control after returning to the diabetes treatment system had changes in their diabetes medication when compared with similar patients who did not show improvement. “LTFs” who had baseline haemoglobin A(1) (c) (HbA(1) (c)) ≥53 mmol/mol and succeeded in reducing HbA(1) (c) ≥ 6 mmol/mol during a 12–30 month follow-up period after adhering again to their diabetes treatment system were compared with “LTFs” who had an unsatisfactory change in HbA(1) (c) or with “LTFs” who maintained good glycaemic control throughout the 12–30 month follow-up period. Unsatisfactory change in HbA(1) (c) was determined as HbA(1) (c) ≥ 53 mmol/mol and change <6 mmol/mol after the 12–30 month follow-up period in their diabetes treatment system or HbA(1) (c) < 53 mmol/mol when returning to the diabetes treatment system but ≥53 mmol/mol at the end of the 12–30 month follow-up period. “LTFs” with improvement in glycaemic control used a higher number of different anti-hyperglycaemic agents (P < 0.001) and their dosages of metformin increased (P < 0.05) when compared with “LTFs” without improvement or “LTFs” with satisfactory glycaemic control. Cholesterol-, LDL-cholesterol- and triglyceride-concentrations decreased during the 12–30 month follow-up period (P < 0.05) in “LTFs” with improved glycaemic control, but not in the other groups. “LTFs” with T2D who had poor glycaemic control seemed to require an increase in their anti-diabetic medication when attempting to improve their glycaemic control. |
format | Online Article Text |
id | pubmed-7448891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74488912020-09-10 A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication Kauppila, Timo Laine, Merja K. Honkasalo, Mikko Raina, Marko Eriksson, Johan G. Int J Circumpolar Health Original Research Article The aim of this study was to evaluate whether patients with type 2 diabetes (T2D) who had stopped attending their diabetes treatment system (referred to as “lost to follow-up”, LTF) but who succeeded in improving their glycaemic control after returning to the diabetes treatment system had changes in their diabetes medication when compared with similar patients who did not show improvement. “LTFs” who had baseline haemoglobin A(1) (c) (HbA(1) (c)) ≥53 mmol/mol and succeeded in reducing HbA(1) (c) ≥ 6 mmol/mol during a 12–30 month follow-up period after adhering again to their diabetes treatment system were compared with “LTFs” who had an unsatisfactory change in HbA(1) (c) or with “LTFs” who maintained good glycaemic control throughout the 12–30 month follow-up period. Unsatisfactory change in HbA(1) (c) was determined as HbA(1) (c) ≥ 53 mmol/mol and change <6 mmol/mol after the 12–30 month follow-up period in their diabetes treatment system or HbA(1) (c) < 53 mmol/mol when returning to the diabetes treatment system but ≥53 mmol/mol at the end of the 12–30 month follow-up period. “LTFs” with improvement in glycaemic control used a higher number of different anti-hyperglycaemic agents (P < 0.001) and their dosages of metformin increased (P < 0.05) when compared with “LTFs” without improvement or “LTFs” with satisfactory glycaemic control. Cholesterol-, LDL-cholesterol- and triglyceride-concentrations decreased during the 12–30 month follow-up period (P < 0.05) in “LTFs” with improved glycaemic control, but not in the other groups. “LTFs” with T2D who had poor glycaemic control seemed to require an increase in their anti-diabetic medication when attempting to improve their glycaemic control. Taylor & Francis 2020-06-05 /pmc/articles/PMC7448891/ /pubmed/32498629 http://dx.doi.org/10.1080/22423982.2020.1773127 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Article Kauppila, Timo Laine, Merja K. Honkasalo, Mikko Raina, Marko Eriksson, Johan G. A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title | A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title_full | A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title_fullStr | A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title_full_unstemmed | A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title_short | A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
title_sort | longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort – positive effect on glycaemic control after changes in medication |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448891/ https://www.ncbi.nlm.nih.gov/pubmed/32498629 http://dx.doi.org/10.1080/22423982.2020.1773127 |
work_keys_str_mv | AT kauppilatimo alongitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT lainemerjak alongitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT honkasalomikko alongitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT rainamarko alongitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT erikssonjohang alongitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT kauppilatimo longitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT lainemerjak longitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT honkasalomikko longitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT rainamarko longitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication AT erikssonjohang longitudinalfollowupstudyofatype2diabeteslosttofollowupcohortpositiveeffectonglycaemiccontrolafterchangesinmedication |